Revenue
2020
2021
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $15.8M | $26.0M | $36.4M | $23.1M | $24.1M | $7.4M |
| Gross profit | $10.9M | $12.8M | $21.0M | $14.9M | $11.9M | $2.6M |
| Operating expenses | $23.4M | $35.3M | $33.3M | $21.4M | $10.5M | $7.4M |
| Operating income | −$12.5M | −$22.5M | −$12.3M | −$6.5M | $1.4M | −$4.8M |
| EBITDAderived | −$11.7M | −$18.8M | −$8.8M | −$3.8M | $2.5M | −$4.2M |
| Net income | −$13.7M | −$23.7M | −$17.5M | −$2.0M | $3.0M | −$5.4M |
| Basic EPSper diluted share | -$1.73 | -$23.03 | -$18.94 | -$0.43 | $0.25 | -$0.53 |
| Diluted EPSper diluted share | -$1.73 | -$23.03 | -$18.94 | -$0.43 | $0.21 | -$0.53 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 23, 2025Form 4 | MARSHALL ALLANChief Executive Officer | BuyCommon Stock | 50.0K | $1.80 | $90.0K | 4.05M |
| Dec 16, 2025Form 4 | MARSHALL ALLANChief Executive Officer | BuyCommon Stock | 50.0K | $2.07 | $103.5K | 4.00M |
| Dec 15, 2025Form 4 | MARSHALL ALLANChief Executive Officer | BuyCommon Stock | 100.0K | $2.07 | $207.0K | 3.95M |
| Nov 20, 2025Form 4 | Salkind GeneDirector | BuyCommon Stock · indirect | 50.0K | $2.55 | $127.5K | 218.8K |
| Nov 17, 2025Form 4 | Salkind GeneDirector | BuyCommon Stock · indirect | 100.0K | $2.81 | $281.0K | 168.8K |